CEO, Board Member
2019-01-01–present
Board Member
Kymera Therapeutics, Inc. (KYMR)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Nello Mainolfi is recorded as CEO and Board Member at Kymera Therapeutics, Inc. (KYMR). The proxy statement of Kymera Therapeutics, Inc. reports total compensation of $8,545,609 for Nello Mainolfi in fiscal 2025, including a base salary of $693,000. Disclosed compensation is on record for 6 fiscal years. Nello Mainolfi has spoken on 16 earnings calls and 3 other investor events across 1 company, most recently for Kymera Therapeutics, Inc. on September 15, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2019-01-01–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2019-01-01–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kymera Therapeutics, Inc. (KYMR) | Founder, President and Chief Executive Officer | $693,000 | $8,545,609 |
| 2024 | Kymera Therapeutics, Inc. (KYMR) | Founder, President and Chief Executive Officer | $670,000 | $15,433,147 |
| 2023 | Kymera Therapeutics, Inc. (KYMR) | Founder, President and Chief Executive Officer | $640,000 | $9,670,542 |
| 2022 | Kymera Therapeutics, Inc. (KYMR) | Founder, President and Chief Executive Officer | $600,000 | $6,926,645 |
| 2021 | Kymera Therapeutics, Inc. (KYMR) | Founder, President and Chief Executive Officer | $570,582 | $11,573,374 |
| 2020 | Kymera Therapeutics, Inc. (KYMR) | Founder, President and Chief Executive Officer | $453,619 | $3,678,001 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.